Surdea-Blaga Teodora, Ismaiel Abdulrahman, Jaaouani Ayman, Leucuta Daniel-Corneliu, Elsayed Abdalla, Ismaiel Mohamed, Ben Ameur Inès, Al Srouji Nahlah, Popa Stefan-Lucian, Grad Simona, Ensar Dilara, Dumitrascu Dan L
2nd Department of Internal Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Dig Dis. 2023;41(6):860-871. doi: 10.1159/000531614. Epub 2023 Jun 29.
Adipose tissue plays an important role in the pathogenesis of inflammatory conditions. The role of adipokines in inflammatory bowel disease (IBD) has been evaluated in the current literature with conflicting results. The aim of this study was to evaluate adiponectin levels in IBD patients, including Crohn's disease (CD) and ulcerative colitis (UC), compared to controls, as well as further subgroup analyses. Hence, assessing the potential role of adiponectin as a surrogate marker.
We performed a systematic electronic search on PubMed, Embase, Scopus, and Cochrane Library, including observational or interventional studies evaluating serum or plasma adiponectin levels in IBD patients in humans. The primary summary outcome was the mean difference (MD) in serum or plasma adiponectin levels between IBD patients versus controls. Subgroup analyses were conducted involving adiponectin levels in CD and UC compared to controls, as well as CD compared to UC.
A total of 20 studies were included in our qualitative synthesis and 14 studies in our quantitative synthesis, with a total population sample of 2,085 subjects. No significant MD in serum adiponectin levels was observed between IBD patients versus controls {-1.331 (95% confidence interval [CI]: -3.135-0.472)}, UC patients versus controls (-0.213 [95% CI: -1.898-1.472]), and CD patients versus controls (-0.851 [95% CI: -2.263-0.561]). Nevertheless, a significant MD was found between UC patients versus CD patients (0.859 [95% CI: 0.097-1.622]).
Serum adiponectin levels were not able to differentiate between IBD, UC, and CD patients compared to controls. However, significantly higher serum adiponectin levels were observed in UC compared to CD patients.
脂肪组织在炎症性疾病的发病机制中起重要作用。目前文献中已对脂肪因子在炎症性肠病（IBD）中的作用进行了评估，但结果相互矛盾。本研究的目的是评估IBD患者（包括克罗恩病（CD）和溃疡性结肠炎（UC））与对照组相比的脂联素水平，并进行进一步的亚组分析。因此，评估脂联素作为替代标志物的潜在作用。
我们在PubMed、Embase、Scopus和Cochrane图书馆进行了系统的电子检索，包括评估人类IBD患者血清或血浆脂联素水平的观察性或干预性研究。主要汇总结果是IBD患者与对照组之间血清或血浆脂联素水平的平均差异（MD）。进行了亚组分析，包括CD和UC患者与对照组相比的脂联素水平，以及CD与UC相比的脂联素水平。
我们的定性综合分析共纳入20项研究，定量综合分析纳入14项研究，总样本量为2085名受试者。IBD患者与对照组之间血清脂联素水平未观察到显著的MD（-1.331（95%置信区间[CI]：-3.135 - 0.472）），UC患者与对照组之间（-0.213[95%CI：-1.898 - 1.472]），以及CD患者与对照组之间（-0.851[95%CI：-2.263 - 0.561]）。然而，UC患者与CD患者之间发现了显著的MD（0.859[95%CI：0.097 - 1.622]）。
与对照组相比，血清脂联素水平无法区分IBD、UC和CD患者。然而，与CD患者相比，UC患者的血清脂联素水平显著更高。
